Joseph F Quinn

List of Publications by Year
in descending order

221 papers	27,014 citations	8181 76 h-index	6836 155 g-index
246 all docs	246 docs citations	246 times ranked	31993 citing authors

#	Article	IF	Citations
1	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
2	Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics, 2011, 43, 436-441.	21.4	1,676
3	The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature, 2011, 477, 90-94.	27.8	1,453
4	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
5	Mitochondria are a direct site of AÎ² accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Human Molecular Genetics, 2006, 15, 1437-1449.	2.9	996
6	Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nature Medicine, 2007, 13, 1359-1362.	30.7	969
7	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
8	Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 304, 1903.	7.4	626
9	DJ-1 and Î±-synuclein in human cerebrospinal fluid as biomarkers of Parkinsonâ€™s disease. Brain, 2010, 133, 713-726.	7.6	575
10	Plasma exosomal Î±-synuclein is likely CNS-derived and increased in Parkinsonâ€™s disease. Acta Neuropathologica, 2014, 128, 639-650.	7.7	504
11	Lipid peroxidation in aging brain and Alzheimerâ€™s disease1,2 1Guest Editors: Mark A. Smith and George Perry 2This article is part of a series of reviews on â€œCauses and Consequences of Oxidative Stress in Alzheimerâ€™s Disease.â€•The full list of papers may be found on the homepage of the journal.. Free Radical Biology and Medicine, 2002, 33, 620-626.	2.9	406
12	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurology, The, 2017, 16, 55-65.	10.2	394
13	An anatomical study of cholinergic innervation in rat cerebral cortex. Neuroscience, 1988, 25, 457-474.	2.3	391
14	YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease. Biological Psychiatry, 2010, 68, 903-912.	1.3	382
15	Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Annals of Neurology, 2011, 69, 570-580.	5.3	371
16	Association of Perivascular Localization of Aquaporin-4 With Cognition and Alzheimer Disease in Aging Brains. JAMA Neurology, 2017, 74, 91.	9.0	367
17	Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. Journal of Alzheimer's Disease, 2006, 9, 293-348.	2.6	362
18	Cerebrospinal Fluid Tau and Î²-Amyloid. Archives of Neurology, 2003, 60, 1696.	4.5	341

#	Article	IF	Citations
19	Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimer's and Dementia, 2009, 5, 18-29.	0.8	322
20	Antioxidants for Alzheimer Disease. Archives of Neurology, 2012, 69, 836-41.	4.5	314
21	Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Human Molecular Genetics, 2004, 13, 1225-1240.	2.9	309
22	APOE Ïµ4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	9.0	302
23	Phase 2 Safety Trial Targeting Amyloid Î² Production With a Î³-Secretase Inhibitor in Alzheimer Disease. Archives of Neurology, 2008, 65, 1031-8.	4.5	298
24	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
25	CSF Multianalyte Profile Distinguishes Alzheimer and Parkinson Diseases. American Journal of Clinical Pathology, 2008, 129, 526-529.	0.7	248
26	Version 3 of the National Alzheimerâ€™s Coordinating Centerâ€™s Uniform Data Set. Alzheimer Disease and Associated Disorders, 2018, 32, 351-358.	1.3	241
27	Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chemistry and Physics of Lipids, 2004, 128, 117-124.	3.2	222
28	A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 111-120.	2.6	210
29	Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Experimental Neurology, 2003, 184, 510-520.	4.1	202
30	Uric Acid as a CNS Antioxidant. Journal of Alzheimer's Disease, 2010, 19, 1331-1336.	2.6	197
31	Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	9.0	185
32	Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neuroscience Letters, 2010, 480, 78-82.	2.1	184
33	Assessment of the genetic variance of late-onset Alzheimer's disease. Neurobiology of Aging, 2016, 41, 200.e13-200.e20.	3.1	174
34	APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease. JAMA Neurology, 2014, 71, 1405.	9.0	172
35	Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12145-12150.	7.1	171
36	Safety and Acceptability of the Research Lumbar Puncture. Alzheimer Disease and Associated Disorders, 2005, 19, 220-225.	1.3	170

#	Article	IF	Citations
37	Effects of Multiple Genetic Loci on Age at Onset in Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1394.	9.0	166
38	Transethnic genomeâ€wide scan identifies novel Alzheimer's disease loci. Alzheimer's and Dementia, 2017, 13, 727-738.	0.8	166
39	Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiology of Aging, 2005, 26, 207-227.	3.1	162
40	CSF AÎ²₄₂ and tau in Parkinson's disease with cognitive impairment. Movement Disorders, 2010, 25, 2682-2685.	3.9	162
41	Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. Journal of Alzheimer's Disease, 2005, 7, 125-133.	2.6	160
42	GBA Variants are associated with a distinct pattern of cognitive deficits in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 95-102.	3.9	158
43	SNCA Variant Associated With Parkinson Disease and Plasma Î±-Synuclein Level. Archives of Neurology, 2010, 67, 1350-6.	4.5	157
44	Peripheral F₂â€isoprostanes and F₄â€neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology, 2002, 52, 175-179.	5.3	156
45	Chronic dietary Î±-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiology of Aging, 2007, 28, 213-225.	3.1	155
46	CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1125-1131.	0.8	154
47	Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease. PLoS ONE, 2011, 6, e16032.	2.5	152
48	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. Cell, 2019, 177, 231-242.	28.9	152
49	Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology, 2012, 79, 221-228.	1.1	144
50	Centella asiatica: phytochemistry and mechanisms of neuroprotection and cognitive enhancement. Phytochemistry Reviews, 2018, 17, 161-194.	6.5	144
51	Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel. JAMA Neurology, 2021, 78, 102.	9.0	144
52	L-type voltage-gated calcium channel blockade with isradipine as a therapeutic strategy for Alzheimer's disease. Neurobiology of Disease, 2011, 41, 62-70.	4.4	133
53	Measurement of Gelatinase B (MMP-9) in the Cerebrospinal Fluid of Patients With Vascular Dementia and Alzheimer Disease. Stroke, 2004, 35, e159-62.	2.0	124
54	Age and Apolipoprotein E*4 Allele Effects on Cerebrospinal Fluid Î²-Amyloid 42 in Adults With Normal Cognition. Archives of Neurology, 2006, 63, 936.	4.5	118

#	Article	IF	Citations
55	Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. Journal of Neuroimmunology, 2003, 137, 32-41.	2.3	117
56	Incidence of New-Onset Seizures in Mild to Moderate Alzheimer Disease. Archives of Neurology, 2012, 69, 368.	4.5	117
57	Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: The case for isradipine. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1584-1590.	3.8	114
58	A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics, 2007, 7, 469-473.	2.2	111
59	F₂-Isoprostanes in Alzheimer and Other Neurodegenerative Diseases. Antioxidants and Redox Signaling, 2005, 7, 269-275.	5.4	106
60	Cerebrospinal Fluid AÎ²42, Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls. Archives of Pathology and Laboratory Medicine, 2001, 125, 510-512.	2.5	106
61	Nutritional Biomarkers in Alzheimer's Disease: The Association between Carotenoids, n-3 Fatty Acids, and Dementia Severity. Journal of Alzheimer's Disease, 2008, 13, 31-38.	2.6	103
62	Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Research, 2005, 1037, 209-213.	2.2	100
63	Association of cognitive domains with postural instability/gait disturbance in Parkinson's disease. Parkinsonism and Related Disorders, 2015, 21, 692-697.	2.2	99
64	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. American Journal of Pathology, 2011, 178, 1509-1516.	3.8	97
65	Non-targeted lipidomics of CSF and frontal cortex grey and white matter in control, mild cognitive impairment, and Alzheimerâ€™s disease subjects. Acta Neuropsychiatrica, 2015, 27, 270-278.	2.1	96
66	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. Free Radical Biology and Medicine, 2008, 45, 219-230.	2.9	95
67	The effects of noncoding aquaporinâ€4 singleâ€nucleotide polymorphisms on cognition and functional progression of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 348-359.	3.7	94
68	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 29-36.	2.2	94
69	MicroRNAs in Human Cerebrospinal Fluid as Biomarkers for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 55, 1223-1233.	2.6	93
70	Evaluation of Coenzyme Q as an Antioxidant Strategy for Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 225-234.	2.6	92
71	Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults. Neurology, 2013, 81, 2024-2027.	1.1	89
72	Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. Journal of Alzheimer's Disease, 2004, 6, 93-97.	2.6	88

#	Article	IF	Citations
73	Identification of Glycoproteins in Human Cerebrospinal Fluid with a Complementary Proteomic Approach. Journal of Proteome Research, 2006, 5, 2769-2779.	3.7	88
74	Biomarkers for cognitive impairment and dementia in elderly people. Lancet Neurology, The, 2008, 7, 704-714.	10.2	85
75	Centella asiatica modulates antioxidant and mitochondrial pathways and improves cognitive function in mice. Journal of Ethnopharmacology, 2016, 180, 78-86.	4.1	84
76	Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. Journal of Clinical Lipidology, 2018, 12, 1169-1178.	1.5	83
77	The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2013, 5, 59.	6.2	80
78	Caffeoylquinic Acids in Centella asiatica Protect against Amyloid-Î² Toxicity. Journal of Alzheimer's Disease, 2014, 40, 359-373.	2.6	78
79	Centella asiaticaExtract Improves Behavioral Deficits in a Mouse Model of Alzheimer's Disease: Investigation of a Possible Mechanism of Action. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	2.0	77
80	People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Movement Disorders, 2014, 29, 1258-1264.	3.9	76
81	Multiple SNPs Within and Surrounding the Apolipoprotein E Gene Influence Cerebrospinal Fluid Apolipoprotein E Protein Levels. Journal of Alzheimer's Disease, 2008, 13, 255-266.	2.6	75
82	Ascorbic Acid and Rates of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 93-98.	2.6	75
83	Extracellular RNAs: development as biomarkers of human disease. Journal of Extracellular Vesicles, 2015, 4, 27495.	12.2	72
84	Targeted Lipidomics of Fontal Cortex andÂPlasma Diacylglycerols (DAG) inÂMildÂCognitive Impairment and Alzheimerâ€™s Disease: Validation ofÂDAGÂAccumulation Early in the Pathophysiology of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 537-546.	2.6	72
85	apoE isoforms and measures of anxiety in probable AD patients and Apoeâˆ’/âˆ’ mice. Neurobiology of Aging, 2005, 26, 637-643.	3.1	69
86	Analysis of extracellular RNA in cerebrospinal fluid. Journal of Extracellular Vesicles, 2017, 6, 1317577.	12.2	68
87	Application of Targeted Quantitative Proteomics Analysis in Human Cerebrospinal Fluid Using a Liquid Chromatography Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Tandem Mass Spectrometer (LC MALDI TOF/TOF) Platform. Journal of Proteome Research, 2008, 7, 720-730.	3.7	67
88	Centella asiatica Attenuates Amyloid-Î²-Induced Oxidative Stress and Mitochondrial Dysfunction. Journal of Alzheimer's Disease, 2015, 45, 933-946.	2.6	67
89	Increased Cerebrospinal Fluid F2-Isoprostanes are Associated with Aging and Latent Alzheimerâ€™s Disease as Identified by Biomarkers. NeuroMolecular Medicine, 2011, 13, 37-43.	3.4	65
90	Memory, Mood, and Vitamin D in Persons with Parkinson's Disease. Journal of Parkinson's Disease, 2013, 3, 547-555.	2.8	65

#	Article	IF	Citations
91	Pacific Northwest Udall Center of Excellence Clinical Consortium: Study Design and Baseline Cohort Characteristics. Journal of Parkinson's Disease, 2013, 3, 205-214.	2.8	64
92	Cognitive profile of LRRK2â€related Parkinson's disease. Movement Disorders, 2015, 30, 728-733.	3.9	64
93	Dyslipidemia and Blood-Brain Barrier Integrity in Alzheimer's Disease. Current Gerontology and Geriatrics Research, 2012, 2012, 1-5.	1.6	63
94	Phytic Acid as a Potential Treatment for Alzheimer's Pathology: Evidence from Animal and in vitro Models. Journal of Alzheimer's Disease, 2011, 23, 21-35.	2.6	62
95	Raman spectroscopy and machine learning for biomedical applications: Alzheimerâ€™s disease diagnosis based on the analysis of cerebrospinal fluid. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2021, 248, 119188.	3.9	61
96	F2-Isoprostanes as Biomarkers of Late-onset Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2007, 33, 114-119.	2.3	60
97	Aberrant Detergent-Insoluble Excitatory Amino Acid Transporter 2 Accumulates in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2010, 69, 667-676.	1.7	59
98	Cognitive impairment and dementia in patients with Parkinson disease. Current Topics in Medicinal Chemistry, 2009, 9, 903-12.	2.1	58
99	Modulation of tau phosphorylation by environmental copper. Translational Neurodegeneration, 2014, 3, 24.	8.0	56
100	The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2016, 8, 25.	6.2	55
101	Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Movement Disorders, 2014, 29, 756-764.	3.9	53
102	Centella asiatica attenuates hippocampal mitochondrial dysfunction and improves memory and executive function in Î²-amyloid overexpressing mice. Molecular and Cellular Neurosciences, 2018, 93, 1-9.	2.2	53
103	Role of soluble epoxide hydrolase in age-related vascular cognitive decline. Prostaglandins and Other Lipid Mediators, 2014, 113-115, 30-37.	1.9	52
104	Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. Journal of Neuroscience Research, 2005, 80, 406-413.	2.9	51
105	Cerebrospinal Fluid Peptides as Potential Parkinson Disease Biomarkers: A Staged Pipeline for Discovery and Validation*. Molecular and Cellular Proteomics, 2015, 14, 544-555.	3.8	51
106	Antioxidants in Alzheimer's disease-vitamin C delivery to a demanding brain. Journal of Alzheimer's Disease, 2003, 5, 309-313.	2.6	50
107	Precision Medicine. American Journal of Pathology, 2016, 186, 500-506.	3.8	49
108	Soluble TREM2 is elevated in Parkinsonâ€™s disease subgroups with increased CSF tau. Brain, 2020, 143, 932-943.	7.6	49

#	Article	IF	Citations
109	Centella asiatica increases hippocampal synaptic density and improves memory and executive function in aged mice. Brain and Behavior, 2018, 8, e01024.	2.2	48
110	Surgery is associated with ventricular enlargement as well as cognitive and functional decline. Alzheimer's and Dementia, 2016, 12, 590-597.	0.8	47
111	Pre-frontal Cortical Activity During Walking and Turning Is Reliable and Differentiates Across Young, Older Adults and People With Parkinson's Disease. Frontiers in Neurology, 2019, 10, 536.	2.4	47
112	Centella Asiatica Improves Memory and Promotes Antioxidative Signaling in 5XFAD Mice. Antioxidants, 2019, 8, 630.	5.1	47
113	Proteomic determination of widespread detergent insolubility, including AÎ² but not tau, early in the pathogenesis of Alzheimer's disease. FASEB Journal, 2005, 19, 1923-1925.	0.5	46
114	Homocysteine and cognitive function in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 44, 1-5.	2.2	44
115	CCR6: A Biomarker for Alzheimer's-like Disease in a Triple Transgenic Mouse Model. Journal of Alzheimer's Disease, 2010, 22, 619-629.	2.6	44
116	Reliability and Validity of Food Frequency Questionnaire and Nutrient Biomarkers in Elders With and Without Mild Cognitive Impairment. Alzheimer Disease and Associated Disorders, 2011, 25, 49-57.	1.3	43
117	Rarity of the Alzheimer Diseaseâ€“ProtectiveAPPA673T Variant in the United States. JAMA Neurology, 2015, 72, 209.	9.0	41
118	Cognitive associations with comprehensive gait and static balance measures in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 104-110.	2.2	41
119	Validation of MicroRNA Biomarkers for Alzheimerâ€™s Disease in Human Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2019, 67, 875-891.	2.6	41
120	Modeling of Pathological Traits in Alzheimer's Disease Based on Systemic Extracellular Signaling Proteome. Molecular and Cellular Proteomics, 2011, 10, M111.008862.	3.8	40
121	Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span. JAMA Neurology, 2014, 71, 742.	9.0	40
122	Common variant rs356182 near SNCA defines a Parkinson's disease endophenotype. Annals of Clinical and Translational Neurology, 2017, 4, 15-25.	3.7	40
123	A translational continuum of model systems for evaluating treatment strategies in Alzheimerâ€™s disease: isradipine as a candidate drug. DMM Disease Models and Mechanisms, 2011, 4, 634-648.	2.4	39
124	Plasma omega-3 PUFA and white matter mediated executive decline in older adults. Frontiers in Aging Neuroscience, 2013, 5, 92.	3.4	39
125	Alzheimerâ€™s disease and the bloodâ€“brain barrier: past, present and future. Aging Health, 2008, 4, 47-57.	0.3	38
126	Serum vitamin d concentrations are associated with falling and cognitive function in older adults. Journal of Nutrition, Health and Aging, 2012, 16, 898-901.	3.3	38

#	Article	IF	Citations
127	Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults. Alzheimer's Research and Therapy, 2017, 9, 48.	6.2	38
128	Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimerâ€™s Disease Cooperative Study-Sponsored DHA Clinical Trial. Journal of Alzheimer's Disease, 2020, 74, 975-990.	2.6	38
129	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. Neurobiology of Aging, 2017, 56, 211.e1-211.e7.	3.1	37
130	Copper in Alzheimerâ€™s disease: too much or too little?. Expert Review of Neurotherapeutics, 2009, 9, 631-637.	2.8	36
131	Oral Zinc Reduces Amyloid Burden in Tg2576 Mice. Journal of Alzheimer's Disease, 2014, 41, 179-192.	2.6	35
132	Sex and genetic differences in postoperative cognitive dysfunction: a longitudinal cohort analysis. Biology of Sex Differences, 2019, 10, 14.	4.1	35
133	Centella asiatica attenuates AÎ²-induced neurodegenerative spine loss and dendritic simplification. Neuroscience Letters, 2017, 646, 24-29.	2.1	34
134	Centella asiatica Attenuates Mitochondrial Dysfunction and Oxidative Stress in AÎ²-Exposed Hippocampal Neurons. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-8.	4.0	34
135	Caffeoylquinic Acids in Centella asiatica Reverse Cognitive Deficits in Male 5XFAD Alzheimerâ€™s Disease Model Mice. Nutrients, 2020, 12, 3488.	4.1	34
136	<scp>Openâ€Label</scp> Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy. Movement Disorders Clinical Practice, 2020, 7, 440-447.	1.5	34
137	Multivariate Statistical Analysis of Surface Enhanced Raman Spectra of Human Serum for Alzheimerâ€™s Disease Diagnosis. Applied Sciences (Switzerland), 2019, 9, 3256.	2.5	33
138	Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimerâ€™s Disease. , 2017, 8, 215.		32
139	The key role of T cells in Parkinson's disease pathogenesis and therapy. Parkinsonism and Related Disorders, 2019, 60, 25-31.	2.2	32
140	A Copper-Lowering Strategy Attenuates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 21, 903-914.	2.6	30
141	Targeted Discovery and Validation of Plasma Biomarkers of Parkinsonâ€™s Disease. Journal of Proteome Research, 2014, 13, 4535-4545.	3.7	30
142	Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid Î² 1â€“42 in CSF for the Diagnosis of Alzheimerâ€™s Disease. Journal of Proteome Research, 2017, 16, 1228-1238.	3.7	30
143	Diagnostic Values of Cerebrospinal Fluid T-Tau and AÎ²42 using Meso Scale Discovery Assays for Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 709-719.	2.6	28
144	Integration of mass spectral fingerprinting analysis with precursor ion (MS1) quantification for the characterisation of botanical extracts: application to extracts of <scp>Centella asiatica</scp> (L.) Urban. Phytochemical Analysis, 2020, 31, 722-738.	2.4	28

#	Article	IF	Citations
145	High-Density Lipoprotein Carries Markers That Track With Recovery From Stroke. Circulation Research, 2020, 127, 1274-1287.	4.5	26
146	Erythrocytic Î±-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinsonâ€™s disease pathogenesis. Acta Neuropathologica Communications, 2020, 8, 102.	5.2	26
147	Multivariate prediction of dementia in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 20.	5.3	25
148	Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy. Movement Disorders, 2020, 35, 2019-2027.	3.9	25
149	Oxidized Products of Omega-6 and Omega-3 Long Chain Fatty Acids Are Associated with Increased White Matter Hyperintensity and Poorer Executive Function Performance in a Cohort of Cognitively Normal Hypertensive Older Adults. Journal of Alzheimer's Disease, 2020, 74, 65-77.	2.6	25
150	Î²-Amyloid Plaques Induce Neuritic Dystrophy of Nitric Oxide-Producing Neurons in a Transgenic Mouse Model of Alzheimer's Disease. Experimental Neurology, 2001, 168, 203-212.	4.1	24
151	The Blood-Brain Barrier and Microvascular Water Exchange in Alzheimer's Disease. Cardiovascular Psychiatry and Neurology, 2011, 2011, 1-9.	0.8	23
152	Influence of Lifestyle Modifications on Age-Related Free Radical Injury to Brain. JAMA Neurology, 2014, 71, 1150.	9.0	23
153	ADAM10 expression and promoter haplotype in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 2229.e1-2229.e9.	3.1	22
154	Associations between <scp>CSF</scp> cortisol and <scp>CSF</scp> norepinephrine in cognitively normal controls and patients with amnestic <scp>MCI</scp> and <scp>AD</scp> dementia. International Journal of Geriatric Psychiatry, 2018, 33, 763-768.	2.7	22
155	Prediction of cognitive progression in Parkinson's disease using three cognitive screening measures. Clinical Parkinsonism & Related Disorders, 2019, 1, 91-97.	0.9	22
156	Open label tissue plasminogen activator for stroke: The Oregon experience. Journal of Stroke and Cerebrovascular Diseases, 1999, 8, 287-290.	1.6	21
157	Blood extracellular vesicles carrying synaptic functionâ€•and brainâ€•related proteins as potential biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 909-923.	0.8	21
158	Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. Journal of Alzheimer's Disease, 2006, 8, 359-367.	2.6	20
159	Review of selected databases of longitudinal aging studies. Alzheimer's and Dementia, 2012, 8, 584-589.	0.8	20
160	STX, a Novel Membrane Estrogen Receptor Ligand, Protects Against Amyloid-Î² Toxicity. Journal of Alzheimer's Disease, 2016, 51, 391-403.	2.6	20
161	Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans. Movement Disorders, 2021, 36, 2094-2103.	3.9	20
162	Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. Psychopharmacology, 2018, 235, 761-770.	3.1	19

#	Article	IF	Citations
163	A Metabolomic Aging Clock Using Human Cerebrospinal Fluid. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 744-754.	3.6	19
164	Î±â€Synuclein Seed Amplification in <scp>CSF</scp> and Brain from Patients with Different Brain Distributions of Pathological Î±â€Synuclein in the Context of Coâ€Pathology and <scp>Nonâ€LBD</scp> Diagnoses. Annals of Neurology, 2022, 92, 650-662.	5.3	19
165	Development of a Sensitive Diagnostic Assay for Parkinson Disease Quantifying Î±-Synucleinâ€“Containing Extracellular Vesicles. Neurology, 2021, 96, e2332-e2345.	1.1	18
166	Cerebrospinal Fluid Biomarkers in Mild Cognitive Impairment and Dementia. Journal of Alzheimer's Disease, 2010, 19, 301-309.	2.6	17
167	Gender Effects on Plasma and Brain Copper. International Journal of Alzheimer's Disease, 2011, 2011, 1-4.	2.0	17
168	Randomized Trial of Marine n-3 Polyunsaturated Fatty Acids for the Prevention of Cerebral Small Vessel Disease and Inflammation in Aging (PUFA Trial): Rationale, Design and Baseline Results. Nutrients, 2019, 11, 735.	4.1	17
169	Loss of NRF2 accelerates cognitive decline, exacerbates mitochondrial dysfunction, and is required for the cognitive enhancing effects of Centella asiatica during aging. Neurobiology of Aging, 2021, 100, 48-58.	3.1	17
170	Prolonged Treatment with Centella asiatica Improves Memory, Reduces Amyloid-Î² Pathology, and Activates NRF2-Regulated Antioxidant Response Pathway in 5xFAD Mice. Journal of Alzheimer's Disease, 2021, 81, 1453-1468.	2.6	17
171	Serum Levels of Î±-Klotho Are Correlated with Cerebrospinal Fluid Levels and Predict Measures of Cognitive Function. Journal of Alzheimer's Disease, 2022, 86, 1471-1481.	2.6	17
172	Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 874-883.	1.7	16
173	Alterations in mitochondrial number and function in Alzheimerâ€™s disease fibroblasts. Metabolic Brain Disease, 2015, 30, 1275-1278.	2.9	16
174	Increased CSF E-Selectin in Clinical Alzheimerâ€™s Disease without Altered CSF AÎ² 42 and Tau. Journal of Alzheimer's Disease, 2015, 47, 883-887.	2.6	15
175	Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntingtonâ€™s Disease Patientsâ€”A Randomized Phase 2 Clinical Trial. Journal of Clinical Medicine, 2020, 9, 3682.	2.4	15
176	Differential Effects of APOE Genotype on MicroRNA Cargo of Cerebrospinal Fluid Extracellular Vesicles in Females With Alzheimerâ€™s Disease Compared to Males. Frontiers in Cell and Developmental Biology, 2022, 10, 864022.	3.7	15
177	Mouse cerebral prostaglandins, but not oxidative damage, change with age and are responsive to indomethacin treatment. Brain Research, 2002, 930, 75-82.	2.2	14
178	Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. Movement Disorders, 2012, 27, 1823-1826.	3.9	14
179	Comparative sensitivity of the MoCA and Mattis Dementia Rating Scaleâ€2 in Parkinson's disease. Movement Disorders, 2019, 34, 285-291.	3.9	13
180	Age-Associated DNA Methylation Patterns Are Shared Between the Hippocampus and Peripheral Blood Cells. Frontiers in Genetics, 2020, 11, 111.	2.3	12

#	Article	IF	Citations
181	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. Frontiers in Neurology, 2021, 12, 805135.	2.4	12
182	Centella asiatica Alters Metabolic Pathways Associated With Alzheimerâ€™s Disease in the 5xFAD Mouse Model of ÃŸ-Amyloid Accumulation. Frontiers in Pharmacology, 2021, 12, 788312.	3.5	12
183	The Impact of the hAPP695SW Transgene and Associated Amyloid-Î² Accumulation on Murine Hippocampal Biochemical Pathways. Journal of Alzheimer's Disease, 2022, 85, 1601-1619.	2.6	12
184	Manifestations of Alzheimerâ€™s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90. Scientific Reports, 2022, 12, 6117.	3.3	12
185	Longitudinal relaxographic imaging of white matter hyperintensities in the elderly. Fluids and Barriers of the CNS, 2014, 11, 24.	5.0	11
186	Participant and Study Partner Reported Impact of Cognition on Functional Activities in Parkinson's Disease. Movement Disorders Clinical Practice, 2020, 7, 61-69.	1.5	11
187	An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-Îµ4 in female patients with Alzheimerâ€™s disease. Nature Aging, 2022, 2, 616-634.	11.6	11
188	Visuospatial functioning is associated with sleep disturbance and hallucinations in nondemented patients with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 803-813.	1.3	10
189	Semantic fluency and processing speed are reduced in non-cognitively impaired participants with Parkinsonâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2021, 43, 469-480.	1.3	10
190	Pharmacokinetics and Pharmacodynamics of Key Components of a Standardized Centella asiatica Product in Cognitively Impaired Older Adults: A Phase 1, Double-Blind, Randomized Clinical Trial. Antioxidants, 2022, 11, 215.	5.1	10
191	An alphaâ€synuclein MRM assay with diagnostic potential for Parkinson's disease and monitoring disease progression. Proteomics - Clinical Applications, 2017, 11, 1700045.	1.6	9
192	Predictive Modeling of Alzheimerâ€™s and Parkinsonâ€™s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid. Metabolites, 2022, 12, 277.	2.9	9
193	Performance of Validated MicroRNA Biomarkers for Alzheimerâ€™s Disease in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2020, 78, 245-263.	2.6	8
194	Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial. Parkinsonism and Related Disorders, 2021, 86, 10-14.	2.2	8
195	Gene-Specific DNA Methylation Linked to Postoperative Cognitive Dysfunction in Apolipoprotein E3 and E4 Mice. Journal of Alzheimer's Disease, 2021, 83, 1251-1268.	2.6	8
196	Phytochemicals in Alzheimer Disease: The Development of Clinical Trials. Pharmaceutical Biology, 2004, 42, 64-73.	2.9	7
197	Hallucinations and Development of Dementia in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2020, 10, 1643-1648.	2.8	7
198	Observation of Reduced Homeostatic Metabolic Activity and/or Coupling in White Matter Aging. Journal of Neuroimaging, 2020, 30, 658-665.	2.0	7

#	Article	IF	Citations
199	Peripheral Blood NRF2 Expression as a Biomarker in Human Health and Disease. Antioxidants, 2021, 10, 28.	5.1	7
200	Biomarkers for Alzheimer's Disease: Showing the Way or Leading Us Astray?. Journal of Alzheimer's Disease, 2012, 33, S371-S376.	2.6	6
201	Association of cerebrospinal fluid AÎ²42 with A2M gene in cognitively normal subjects. Neurobiology of Aging, 2014, 35, 357-364.	3.1	6
202	DCE-MRI of Brain Fluid Barriers: In Vivo Water Cycling at the Human Choroid Plexus. Tissue Barriers, 2022, 10, 1963143.	3.2	6
203	Relationships Between Sensorimotor Inhibition and Mobility in Older Adults With and Without Parkinsonâ€™s Disease. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 630-637.	3.6	6
204	Detecting Alzheimer disease before it happens. Neurology, 2008, 71, 78-79.	1.1	4
205	MRI Substudy Participation in Alzheimer Disease (AD) Clinical Trials. Alzheimer Disease and Associated Disorders, 2009, 23, 333-336.	1.3	4
206	Copper Modulation and Memory Impairment due to Hippocampal Tau Pathology. Journal of Alzheimer's Disease, 2020, 78, 49-60.	2.6	4
207	Centella asiatica Water Extract Shows Low Potential for Cytochrome P450â€“Mediated Drug Interactions. Drug Metabolism and Disposition, 2020, 48, 1053-1063.	3.3	4
208	Lost in Translation? Finding Our Way To Effective Alzheimerâ€™s Disease Therapies. Journal of Alzheimer's Disease, 2018, 64, S33-S39.	2.6	3
209	Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease. Frontiers in Neurology, 2020, 11, 893.	2.4	3
210	Cerebrospinal Fluid MicroRNA Changes in Cognitively Normal Veterans With a History of Deployment-Associated Mild Traumatic Brain Injury. Frontiers in Neuroscience, 2021, 15, 720778.	2.8	3
211	Relapsing polychondritis: an uncommon cause of dementia. BMJ Case Reports, 2009, 2009, bcr0820080740-bcr0820080740.	0.5	3
212	Vascular Dementia. Journal of the American Medical Directors Association, 2003, 4, S155-S161.	2.5	3
213	Comment: Gene-environment interactions in dementiaâ€”. Neurology, 2016, 86, 2069-2069.	1.1	2
214	Do Ï‰-3 Fatty Acids Regulate Cerebral Î² Amyloid?. JAMA Neurology, 2016, 73, 1183.	9.0	2
215	Developing a Rational, Optimized Product of Centella asiatica for Examination in Clinical Trials: Real World Challenges. Frontiers in Nutrition, 2021, 8, 799137.	3.7	2
216	Novel antigenic determinant expressed in neurons of the dorsolateral hypothalamus in rat and human. Journal of Neuroscience Research, 1992, 31, 715-723.	2.9	1

#	Article	IF	Citations
217	Cognition as a mediator for gait and balance impairments in GBA-related Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, .	5.3	1
218	Phytochemicals in Alzheimer Disease: The Development of Clinical Trials. Archives of Physiology and Biochemistry, 2004, 42, 64-73.	2.1	0
219	Failure of Biomarkers in Clinical Trials of Alzheimer's Disease: Blaming the Messenger?. Journal of Alzheimer's Disease, 2009, 18, 103-104.	2.6	0
220	Analytics of Cerebrospinal Fluid MicroRNA Quantitative PCR Studies. Molecular Neurobiology, 2019, 56, 4988-4999.	4.0	0
221	F2-Isoprostanes as Biomarkers of Late Onset Alzheimerâ€™s Disease. Oxidative Stress and Disease, 2005, , 147-157.	0.3	0